Skip to main content
SpringerLink
Log in

Multimodal Treatment Plans in Prostate Cancer

  • Chapter
  • First Online:
Chemotherapy and Immunotherapy in Urologic Oncology

  • 518 Accesses

Abstract

There are a variety of options that can be utilized in the detection, prevention, and treatment of prostate cancer. This chapter focuses specifically on postoperative radiotherapy and its use in both the adjuvant and salvage setting following radical prostatectomy. Indications for the utilization of prostate cancer genomic biomarkers are also reviewed. The utility of genomic biomarkers in prostate cancer early diagnosis and long-term outcomes are discussed. Finally, the ability of biomarkers to influence management decisions and assist in the prevention of overtreatment is explored.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

  1. Winter A, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017;119(4):550–9.

    Article  PubMed  Google Scholar 

  2. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23.

    Article  PubMed  PubMed Central  Google Scholar 

  3. D’Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  4. Patrikidou A, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis. 2014;17(4):348–52.

    Article  CAS  PubMed  Google Scholar 

  5. Pignot G, et al. Systemic treatments for high-risk localized prostate cancer. Nat Rev Urol. 2018;15(8):498–510.

    Article  CAS  PubMed  Google Scholar 

  6. Mottet N, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

    Article  PubMed  Google Scholar 

  7. Budaus L, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108(8):1256–61.

    Article  PubMed  Google Scholar 

  8. Silberstein JL, et al. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer. 2011;117(21):4855–60.

    Article  PubMed  Google Scholar 

  9. Tsai HK, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24.

    Article  PubMed  Google Scholar 

  10. Fossati N, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol. 2016;69(4):728–33.

    Article  PubMed  Google Scholar 

  11. Wiegel T, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27(18):2924–30.

    Article  PubMed  Google Scholar 

  12. Herrera FG, Berthold DR. Radiation therapy after radical prostatectomy: implications for clinicians. Front Oncol. 2016;6:117.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Davis JW. Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU Int. 2014;114(3):320–2.

    PubMed  Google Scholar 

  14. Heidenreich A, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.

    Article  PubMed  Google Scholar 

  15. Fossati N, et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol. 2017;71(6):886–93.

    Article  PubMed  Google Scholar 

  16. Swanson GP, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25(16):2225–9.

    Article  PubMed  Google Scholar 

  17. Bolla M, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.

    Article  PubMed  Google Scholar 

  18. Bolla M, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.

    Article  PubMed  Google Scholar 

  19. Valicenti RK, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013;86(5):822–8.

    Article  PubMed  Google Scholar 

  20. Thompson IM, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol. 2013;190(2):441–9.

    Article  PubMed  Google Scholar 

  21. Wallis CJ, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352:i851.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Huang J, et al. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol. 2011;98(1):81–6.

    Article  PubMed  Google Scholar 

  23. Berrington de Gonzalez A, et al. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2015;91(2):295–302.

    Article  PubMed  Google Scholar 

  24. Matta R, et al. Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review. Eur Urol. 2019;75(3):464–76.

    Article  PubMed  Google Scholar 

  25. Zelefsky MJ, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012;110(11):1696–701.

    Article  PubMed  Google Scholar 

  26. Grizzi F, et al. Prostate cancer: from genomics to the whole body and beyond. Biomed Res Int. 2017;2017:8707690.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Lecarpentier J, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 2017;35(20):2240–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Grasso CS, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet. 2009;10(2):77–82.

    Article  CAS  PubMed  Google Scholar 

  30. Loeb S, Ross AE. Genomic testing for localized prostate cancer: where do we go from here? Curr Opin Urol. 2017;27(5):495–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Bratt O, et al. Hereditary prostate cancer: clinical characteristics and survival. J Urol. 2002;167(6):2423–6.

    Article  CAS  PubMed  Google Scholar 

  32. Dalela D, et al. Contemporary role of the decipher(R) test in prostate cancer management: current practice and future perspectives. Rev Urol. 2016;18(1):1–9.

    PubMed  PubMed Central  Google Scholar 

  33. Freedland SJ, et al. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. Eur Urol. 2016;70(4):588–96.

    Article  PubMed  Google Scholar 

  34. Den RB, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33(8):944–51.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Den RB, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89(5):1038–46.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Fine ND, et al. Genomic classifiers for treatment selection in newly diagnosed prostate cancer. BJU Int. 2019;124(4):578–86.

    Google Scholar 

  37. Cuzick J, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bishoff JT, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014;192(2):409–14.

    Article  PubMed  Google Scholar 

  40. Freedland SJ, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(5):848–53.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Shore N, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014;30(4):547–53.

    Article  PubMed  Google Scholar 

  42. Knezevic D, et al. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cullen J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68(1):123–31.

    Article  PubMed  Google Scholar 

  44. Klein EA, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, MD Anderson Cancer Center at Cooper, Camden, NJ, USA

    Rachel Lin Flanagan

  2. Department of Surgery, MD Anderson Cancer Center at Cooper, Cooper Medical School of Rowan University, Camden, NJ, USA

    Jeffrey John Tomaszewski

Authors
  1. Rachel Lin Flanagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey John Tomaszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Edouard J. Trabulsi

  2. Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Costas D. Lallas

  3. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Anne E. Lizardi-Calvaresi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Flanagan, R.L., Tomaszewski, J.J. (2021). Multimodal Treatment Plans in Prostate Cancer. In: Trabulsi, E.J., Lallas, C.D., Lizardi-Calvaresi, A.E. (eds) Chemotherapy and Immunotherapy in Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-52021-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52021-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52020-5

  • Online ISBN: 978-3-030-52021-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation